Rodman & Renshaw initiated coverage of Ascentage Pharma (AAPG) with a Buy rating and $48 price target
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AAPG:
- Ascentage Pharma Wins FDA IND Clearance for BTK Degrader APG-3288 to Enter Global Phase I Trial
- Ascentage Pharma’s APG-3288 receives IND clearance from FDA
- Ascentage Pharma to Present at J.P. Morgan Healthcare Conference
- Ascentage Pharma initiated with a Buy at Lucid Capital
- Ascentage Pharma Showcases Promising Data for Olverembatinib at ASH 2025